Denmark announces suspension of AstraZeneca vaccine
Datetime: 2021-04-16 14:22:36
On April 14th, novel coronavirus pneumonia and the Drug
Administration jointly announced a joint news conference between the National
Health Bureau of Denmark and the drug administration. The joint vaccine
developed by British AstraZeneca pharmaceutical company and University of
Oxford was removed from the national new crown vaccination program. Erickson,
the Danish drug safety agency director, collapsed suddenly.
On April 7, the European Drug Administration conducted an
investigation into the safety of the vaccine and concluded that the vaccine did
have the risk of causing side effects of thrombosis. Novel coronavirus
pneumonia was considered to be "real risk" between the vaccine and
severe side effects, so the vaccine was removed from the new crown vaccination
program, Brost Len, director of Danish National Health Bureau, said at a press
conference.
At a press conference in Denmark to announce
the suspension, Eriksson, acting director of the Danish drug safety department,
suddenly collapsed on the ground at the press conference and was rushed to the
hospital for treatment by the staff nearby. The source said Eriksson was in good
health after he was sent to the hospital, but the specific reason for his
fainting has not been disclosed.
"We estimate that there is one case of vaccine induced
thrombosis or thrombocytopenia in every 40000 people who have been vaccinated
with this vaccine, which we didn\'t know when we started using the AstraZeneca
vaccine," said brostellen, director of the Danish national health service
Denmark became the first country to announce the
discontinuation of the AstraZeneca vaccine. Previously, Denmark has suspended
the vaccination since March 11 due to thrombosis and at least one fatal case.